Open AccessVISUAL MEDIAL TEMPORAL ATROPHY SCALES IN CLINICIAN PRACTICE
Author(s) -
Karen Luiza Ramos Socher,
Douglas Mendes Nunes,
Deborah Lopes,
Artur Martins Coutinho,
Daniele de Paula Faria,
Paula Squarzoni,
Geraldo Busatto Filho,
Carlos Buchpighel,
Ricardo Nitríni,
Sônia Maria Dozzi Brucki
Publication year - 2021
Publication title -
dementia and neuropsychologia
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 0.54
H-Index - 21
ISSN - 1980-5764
DOI - 10.5327/1980-5764.rpda102
Subject(s) - atrophy , biomarker , entorhinal cortex , magnetic resonance imaging , medicine , dementia , pathology , temporal lobe , clinical dementia rating , montreal cognitive assessment , psychology , audiology , oncology , disease , radiology , psychiatry , hippocampus , biology , biochemistry , epilepsy
Background: Visual atrophy scales from the medial temporal region are auxiliary biomarker methods in Alzheimer’s Disease(AD).They may correlated with progression from preclinical to clinical AD. Objective: We aimed to compare medial temporal lobe atrophy (MTA) and entorhinal cortex atrophy (ERICA) scales for magnetic resonance image as a useful tool for probable AD diagnosis and evaluate their accuracy, sensitivity and specificity, regarding clinical diagnosis and 11C-PIB-PET. Methods: 2 neurologists blinded to diagnosis classified 113 adults (over 65y) through MTA and ERICA scales and correlated with sociodemographic data, amyloid brain cortical burden through the 11C-PIB-PET and clinical cognitive status, divided into 30 cognitive unimpaired (CU) individuals, 52 MCI and 31 dementia compatible with AD (DCAD). Results: Inter-rater reliability of these atrophy scales was excellent (0.8- 1) by Cohen analysis. CU group had significantly lower MTA scores (median value 0) than ERICA (median value 1)for both hemispheres. 11C-PIB-PET was positive in 45% of the whole sample. In MCI and DCAD groups, ERICA depicted greater sensitivity and MTA greater specificity. Accuracy was under 70% for both scores in all clinical groups. Conclusion: Our study achieved a moderate sensitivity for ERICA score and could be a better screening tool for DCAD or MCI than MTA score. But, none of them could be considered a useful biomarker in preclinical AD.